Switch to:
More From Other Websites
Big Pharma Pushes Back on Drug-Price Complaints Mar 01 2017
How Gilead’s Liver Disease Drugs Portfolio Performed Mar 01 2017
AstraZeneca’s Symbicort: Dominant Player in Inhaler Segment Mar 01 2017
[$$] Cancer Test Makers Raise Nearly $1 Billion Mar 01 2017
Emerging Markets Expected to Be AstraZeneca’s Key Growth Driver Mar 01 2017
AstraZeneca’s New Products May Offer 2017 Growth Opportunities Mar 01 2017
Label Expansion Expected to Boost Keytruda’s 2017 Revenue Mar 01 2017
Cramer Remix: How drug stocks fulfilled their destiny wit... Feb 28 2017
[$$] OrbiMed Logs Two Decades of Novel Attacks on Cancer Feb 28 2017
Cramer: This Drug Rally Is No Longer 'Trumped Up' Feb 28 2017
MERCK & CO., INC. Files SEC form 10-K, Annual Report Feb 28 2017
AstraZeneca Expects Fall in Net Profit Margins in 2017 Feb 28 2017
Why AstraZeneca’s Revenues Are Expected to Fall in 2017 Feb 28 2017
Merck Announces Second-Quarter 2017 Dividend Feb 28 2017
What Analysts Are Recommending for AstraZeneca in 2017 Feb 28 2017
Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious... Feb 28 2017
UK rejects Merck's Keytruda as initial treatment for lung cancer Feb 28 2017
UK rejects Merck's Keytruda as initial treatment for lung cancer Feb 28 2017
Januvia, Vaccines May Drive Merck’s Revenue Growth in 2017 Feb 28 2017
Respiratory Segment: AstraZeneca’s Growth Platform Feb 28 2017


Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK